Detailseite
Projekt Druckansicht

Kooperierende Mutationen in der AML: Funktionelle Analyse des kooperierenden Netzwerkes der rekurrenten Mutationen RUNX1, ASXL1 und IDH2

Antragstellerin Dr. Friederike Pastore
Fachliche Zuordnung Hämatologie, Onkologie
Förderung Förderung von 2014 bis 2017
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 257981898
 
Erstellungsjahr 2020

Zusammenfassung der Projektergebnisse

After generation of BMT and primary Runx1/Asxl1/Idh1 mouse models we concluded that the probability of success and moreover the novelty of these project was low since the phenotype of the mice did not result in an AML and was similar to Runx1 deleted mice alone. I therefore changed my work topic on a number of independent projects. Amongst others, I investigated the role of PRMT5 in MPN pathogenesis and aimed to elucidate key PRMT5 targets contributing to MPN maintenance. PRMT5 is overexpressed in primary MPN cells and PRMT5 inhibition potently reduced MPN cell proliferation ex vivo. PRMT5 inhibition was efficacious at reversing elevated hematocrit, leukocytosis and splenomegaly in a model of JAK2V617F+ polycythemia vera (PV) and leukocyte and platelet counts, hepatosplenomegaly and fibrosis in the MPLW515L model of myelofibrosis (MF). Dual targeting of JAK and PRMT5 was superior to JAK/PRMT5 inhibitor, further decreasing elevated counts and extramedullary hematopoiesis in vivo. PRMT5 inhibition reduced expression of E2F targets and altered the methylation status of E2F1 leading to attenuated DNA damage repair, cell cycle arrest and increased apoptosis. Our data link PRMT5 to E2F1 regulatory function and MPN cell survival and provide a strong mechanistic rationale for clinical trials of PRMT5 inhibitors in MPN. Pharmacological inhibition of PRMT5 alters the methylation status of E2F1 and shows efficacy in JAK2V617F/MPLW515L MPN models and primary samples. PRMT5 represents a potential novel therapeutic target for MPN, which is now being clinically evaluated. Results from this project have been used to support the planning and scientifical rational for the clinical investigation of a novel PRMT5 inhibitor in MPN in a Phase I clinical trial (NCT03886831).

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung